Upstream / Downstream


Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, November 30th.

Thank you for your patience.


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


We recommend the following alternatives

W IP   IF     H
170-220 Rabbit

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

MRP1/ABCC Antibody recognizes endogenous levels of total MRP1 protein. This antibody does not cross-react with other MRP proteins.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln271 of human MRP1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of ATP-binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion transporter. It has a broad range of substrates, including antineoplastic or therapeutic agents and the glutathione (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates such as folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins (2,3).

Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 has been found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate cancer (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of therapeutic agents from cancer cells and confers drug resistance in those patients. Research studies also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast cancer and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity of chemotherapeutic agents in those patients (6-10).

1.  Cole, S.P. et al. (1992) Science 258, 1650-4.

2.  Pajic, M. et al. (2005) Cancer Lett 228, 241-6.

3.  Deeley, R.G. and Cole, S.P. (2006) FEBS Lett 580, 1103-11.

4.  Atalay, C. et al. (2006) Tumour Biol 27, 309-18.

5.  Sánchez, C. et al. (2011) Prostate 71, 1810-7.

6.  Nooter, K. et al. (1997) Br J Cancer 76, 486-93.

7.  Hsia, T.C. et al. (2002) Lung 180, 173-9.

8.  Kuo, T.H. et al. (2003) Nucl Med Biol 30, 627-32.

9.  Sánchez, C. et al. (2009) Prostate 69, 1448-59.

10.  Vulsteke, C. et al. (2013) Ann Oncol 24, 1513-25.

Entrez-Gene Id 4363
Swiss-Prot Acc. P33527

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.

MRP1/ABCC1 Antibody